Devi Nisha, Singh Dharmender, Rawal Ravindra K, Bariwal Jitender, Singh Virender
Department of Chemistry, Dr B R Ambedkar National Institute of Technology, Jalandhar 144011, India.
Curr Top Med Chem. 2016;16(26):2963-2994. doi: 10.2174/1568026616666160506145539.
The imidazo[1,2-a]pyridine scaffold is recognized as a privileged structure as it represents a promising area for identification of lead structures towards the discovery of new synthetic drug molecules. Several commercial drugs such as Zolpidem, Olprinone, Soraprazan and many other compounds in biological testing and preclinical evaluation, illustrate the wide therapeutic spectrum in this class of drug scaffolds. The present manuscript represents the assimilation of literature pertaining to medicinal aspects of this pharmacophore including the structure-activity relationships.
咪唑并[1,2 - a]吡啶骨架被认为是一种优势结构，因为它是发现新的合成药物分子的先导结构识别的一个有前景的领域。几种商业药物，如唑吡坦、奥普力农、索拉唑以及许多处于生物测试和临床前评估阶段的其他化合物，都说明了这类药物骨架具有广泛的治疗谱。本手稿总结了与该药效团的药用方面相关的文献，包括构效关系。
